UBS raised the firm’s price target on Delek US (DK) to $42 from $31 and keeps a Neutral rating on the shares. Delek US is one of the biggest beneficiaries of Small Refinery Exemptions, and the company should continue to get full exemptions for at least two refining assets under the Trump administration, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DK:
- Delek US price target raised to $40 from $34 at Morgan Stanley
- Delek US price target raised to $47 from $39 at Piper Sandler
- Delek US price target raised to $36 from $28 at TD Cowen
- Delek US price target raised to $45 from $37 at Mizuho
- Delek US Holdings: Hold Rating Maintained Amid Improved Earnings and Future Uncertainties